{
    "clinical_study": {
        "@rank": "159607", 
        "arm_group": [
            {
                "arm_group_label": "Placebo Starch", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Yogurt with about 45 g/day of placebo starch (amylopectin)."
            }, 
            {
                "arm_group_label": "Experimental Starch", 
                "arm_group_type": "Experimental", 
                "description": "Yogurt with about 45 g/day of slowly digestible starch (amylose)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effect of a slowly digesting starch on gut\n      bacteria, sugar and fat metabolism, hunger hormones, and body fat in people with\n      pre-diabetes."
        }, 
        "brief_title": "Role of Slowly Digesible Starch on Diabetes Risk Factors(STARCH)", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Prediabetes", 
        "condition_browse": {
            "mesh_term": [
                "Glucose Intolerance", 
                "Prediabetic State"
            ]
        }, 
        "detailed_description": {
            "textblock": "In a double blind randomized controlled clinical trial, the investigators will test the\n      effect of slowly digesting starch (amylose) versus a placebo starch (amylopectin) on risk\n      factors for type 2 diabetes.  For the study, about 95 obese participants (ages 35-65) with\n      pre-diabetes (impaired fasting glucose) will consume a yogurt containing about 45 g of\n      either the experimental or placebo starch daily for 3 months.  The investigators will test\n      the hypothesis that, compared to controls, a daily intake of 45 g of amylose for 3 months\n      will improve risk factors for the development of type 2 diabetes (insulin sensitivity and\n      secretion) by decreasing ectopic fat depots and decreasing inflammation in parallel with a\n      change in colonic microbial populations."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Have a body mass index between 30 and 44.9 kg/m2\n\n          -  Are 35-65 years of age\n\n          -  Have pre-diabetes, which means impaired fasting glucose (IFG)\n\n          -  Are willing to complete nutritional and activity questionnaires and 2-3 weeks of\n             baseline testing\n\n          -  Are willing to enroll in the 3-month intervention and maintain the same level of\n             exercise during the study\n\n          -  Are willing to maintain weight throughout the study\n\n        Exclusion Criteria\n\n          -  Have evidence of cardiovascular disease, diabetes, symptomatic cholelithiasis\n             (gallstones), or cancer\n\n          -  Have a fasting blood glucose less than 100 mg/dL or greater than 125 mg/dL\n\n          -  Have an average screening blood pressure > 150/100 mm Hg\n\n          -  Are a pre-menopausal woman but do not have a regular menstrual cycle\n\n          -  Are pregnant or breastfeeding\n\n          -  Chronically use medications including diuretics, steroids, and adrenergic-stimulating\n             agents\n\n          -  Have emotional problems such as clinical depression or other diagnosed psychological\n             conditions\n\n          -  Use hormonal contraceptives, oral or parenteral glucocorticoids, or any other\n             medication known to influence glucose or insulin homeostasis (balance), within 1\n             month of study\n\n          -  Have a clinically significant gastrointestinal malabsorption syndrome, chronic\n             diarrhea, or use antibiotics within one month of study\n\n          -  Have abnormal laboratory markers (e.g., elevated potassium levels, hemoglobin or\n             hematocrit below the lower limit of normal)\n\n          -  Chronically consume alcohol (> 4 servings per day) or actively smoke cigarettes (>\n             1/4 pack per day)\n\n          -  Are on any chronic medication that has not had a stable dose for 1 month or longer\n\n          -  Are required to perform of any kind of heavy physical activity\n\n          -  Have metal objects in the body, such as a pacemaker, metal pins, bullet, etc."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "95", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01708694", 
            "org_study_id": "PBRC12009"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo Starch", 
                "description": "One group of participants will consume a yogurt containing 45 g of amylose (the slowly digesting starch) for 3 months.", 
                "intervention_name": "Amylose", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Experimental Starch", 
                "description": "The second group will consume a yogurt containing 45 g of a different starch called amylopectin (the \"placebo\") for 3 months.", 
                "intervention_name": "Amylopectin", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "contact": {
                "email": "recruiters@pbrc.edu", 
                "last_name": "recruiting", 
                "phone": "225-763-3000"
            }, 
            "facility": {
                "address": {
                    "city": "Baton Rouge", 
                    "country": "United States", 
                    "state": "Louisiana", 
                    "zip": "70808"
                }, 
                "name": "Pennington Biomedical Research Center"
            }, 
            "investigator": [
                {
                    "last_name": "Eric Ravussin, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Frank Greenway, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Corby K. Martin, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Courtney M. Peterson, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Roy Martin, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mike Keenan, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kayanush Aryana, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Maria Marco, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Role of Slowly Digesible Starch on Diabetes Risk Factors(STARCH)", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Insulin sensitivity and secretion will be assessed via a Frequently Sampled Intravenous Glucose Tolerance Test (FSIGTT).", 
            "measure": "Insulin Sensitivity and Secretion", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01708694"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Pennington Biomedical Research Center", 
            "investigator_full_name": "Eric Ravussin", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "DXA and MRS will be performed to measure body composition (adipose, muscle, bone mineral content) and to measure hepatic and intramyocellular lipids, respectively.", 
                "measure": "Body Composition", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Stool samples will be collected and fecal bacteria diversity will be measured in conjunction with metagenomic analysis.", 
                "measure": "Gut Microbiota", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Satiety hormones will be measured following ingestion of a standardized smoothie (Standard Meal Test).  Satiety will be measured through visual analogue scales (VAS), remote food photography, and a food intake test.", 
                "measure": "Satiety", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Hunger will be measured through visual analogue scales (VAS), remote food photography, and a food intake test.", 
                "measure": "Hunger", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Pennington Biomedical Research Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pennington Biomedical Research Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}